Circulating mixed cryoglobulins are detected in 40 to 60% of chronically infected hepatitis C virus (HCV) patients whereas overt cryoglobulinemia vasculitis (CryoVas) is observed in about 15% of cases [1] [2] [3] . The prognosis is variable and highly dependent on renal involvement or on the extent of vasculitis lesions 4 .
Treatment of HCV-CryoVas is challenging [5] [6] [7] . Sustained virological response is the main goal in these patients since clinical remission of vasculitis is closely associated with viral clearance 8 . Few studies have reported promising results on the effectiveness and tolerance of direct acting antiviral drugs (DAA), either in association with interferon (IFN) or using IFN-free regimens [8] [9] [10] [11] . The aim of the present study was to evaluate effectiveness and tolerance of an all oral IFN-and ribavirin-free regimen with sofosbuvir plus daclatasvir in patients with cryoglobulinemia vasculitis.
Main clinical features included purpura (75.6%), arthralgia (63.4%), peripheral neuropathy (51.2%), skin ulcers (17.1%), glomerulonephritis (12.2%), and gut involvement and myocarditis (2.4%).
At week 24, thirty-seven (90.2%) patients were complete clinical responders and four (9.8%) were partial responders ( Table 1) . Partial response was due to persistent kidney insufficiency (n=2) or peripheral neuropathy (n=2) while skin and joint involvement disappeared. Median time to achieve a clinical response was twelve weeks. The incidence of complete remission at 3, 6 and 12 months was 85% (74-96), 90% (81-99), and 90% (81-99), respectively. The event free survival at 2 years was 100%. A sustained virological response at week 12 after treatment was noted in all cases. The alanine aminotransferase level decreased from 55.3 ± 6.4 to 20.4 ± 2.0 IU/L, (p<0.0001).
Disappearance of cryoglobulin was evidenced in fifty percent of cases. significantly reverted after DAA therapy (1.7% ± 0.3% versus 2.3% ± 0.16%; 28.4% ± 5.5% versus 18.7% ± 6.5%; 2.7% ± 0.5% versus 1.1% ± 0.2%; and 2.9% ± 0.9% versus 1.6% ± 0.5%, respectively; p<0.05 for all) (Figure 1) . We did not observe significant difference in frequency of CD4 + IFNγ + before versus after DAA therapy (27% ± 2.9% versus 25.9% ± 2.8%, P = 0.91). 
Regulatory T cells deficiency (Tregs), IgM

Flow cytometry
PBMCs were obtained by density-gradient centrifugation. PBMCs were stained with the following monoclonal antibodies (at predetermined optimal dilutions) for 30 minutes at 4°C: 
Safety assessments
Data on all adverse events were collected prospectively during the follow-up.
Statistical analysis
Data are expressed as the mean, standard error of mean (SEM) or median [interquartile range (IQR)] for quantitative data and counts, and percent for categorical data. This study was not designed to evaluate formal statistical hypotheses, and no sample-size calculations were performed. Analyses of effectiveness, tolerance and baseline patient characteristics were performed on the intention-to-treat population, defined as all enrolled patients who received at least one dose of study drugs (sofosbuvir, daclatasvir).
The nonparametric Mann Withney test was used to compare continuous variables. All tests are 2-sided at the 0.05 level. Statistical analyses were performed using GraphPad Prism version 6.0 (GraphPad Software, San Diego, Calif).
Results
Characteristics of HCV-CryoVas patients
Main patient characteristics are detailed in Supplementary Table 1 Table 1 ).
Treatment Efficacy
The main treatment-related data are summarized in Table 1 , Supplementary Table 2 and Supplementary Figures 1 and 2 Figure 1) .
Mean creatinine level was 116±23 µmol/L at baseline and 76±6 µmol/L at week 24, while mean GFR was 88±32 and 89±9 mL/min/1.73/m², respectively (Supplementary Figure 2) . 
